Mike Kreitzinger Joins Biocartis as Senior VP of Global Business Development

Biocartis Group of Companies (Biocartis) has appointed Mike Kreitzinger as senior vice president (SVP) of Global Business Development, effective Aug. 18.

Kreitzinger and his team will focus on sourcing and executing partnership opportunities and forging alliances to drive commercial growth and expand the global integration of Biocartis solutions into the precision oncology ecosystem.

With a career spanning more than 25 years in clinical diagnostics, Kreitzinger brings a unique blend of business strategy, clinical diagnostic sales, and commercial leadership expertise to Biocartis. Most recently, he was senior director of Clinical Strategy and Partnerships at Illumina, where he led the development and implementation of comprehensive strategic clinical plans to bring next-generation sequencing closer to the patient and aligned partnerships to accelerate adoption of genomics in the clinic. Before that, Kreitzinger held various senior commercial leadership roles at Illumina and led U.S. sales at other companies, including Cepheid (a Danaher company) and Alere, now part of Abbott Diagnostics.

Kreitzinger earned an MBA from Florida Gulf Coast University and bachelor of arts degree from Florida State University.

“I am honored to join the team at Biocartis as we advance the mission of providing rapid oncology biomarker results. Cancer is a disease of the genome, and rapid assessment enables providers the answers they need…when they need them,” Kreitzinger said. “I am joining Biocartis to help shape the future of cancer care and look forward to establishing partnerships to bring ultra-fast biomarker testing closer to patients and their physicians.”

Biocartis’ proprietary Idylla Platform delivers in-house molecular biomarker results in three hours, enabling healthcare professionals to make timely, informed decisions that guide personalized therapy. The Itasca, Ill.-based firm’s expanding portfolio of diagnostic tests and research assays addresses key unmet clinical needs across multiple cancers, including lung, skin, thyroid, colorectal, endometrial, blood, brain, and breast cancer.